NCT07860957Completed
Midday Bright Light Therapy for Bipolar Depression
Midday Bright Light Therapy for Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This randomized, double-blind, placebo-controlled study evaluated adjunctive midday bright light therapy in adults with bipolar I or II disorder experiencing mild-to-moderate depression. Participants received either 10,000-lux bright light or 1,500-lux placebo light at home for 30 minutes daily between 12:00 PM and 2:00 PM for four weeks while continuing unchanged pharmacological treatment. The primary outcome was remission at week 4, defined as a total score below 9 on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version. Secondary outcomes included clinical status, psychosocial functioning, sleep quality, circadian characteristics, and adverse effects.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 1 Oct 2026
- Start date
- 1 Apr 2021
- Primary completion date
- 11 Jun 2026
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Bipolar disorder
- NCT number
- NCT07860957
What you commit to
- Study type: Interventional
- Participants enrolled: 37
- From 1 Apr 2021 to the primary completion date, 11 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications that may cause photosensitivity.
Other illness
- Substance use disorder within the preceding 6 months.
- Chronic ophthalmological disease.
Other
- Manic, hypomanic, or mixed episode within the preceding 6 months.
- Active suicidal ideation.
- Acute or chronic psychotic symptoms.
- Shift work.
Who the study is looking for
- Age 18-65 years.
- Diagnosis of bipolar I or bipolar II disorder according to DSM-5 criteria.
- Current mild-to-moderate depressive episode, defined as a 17-item Hamilton Depression Rating Scale (HAM-D-17) score of 8-18.
- No hypomanic or mixed symptoms, defined as a Young Mania Rating Scale (YMRS) score ≤7.
- Treatment with a mood stabilizer and/or an atypical antipsychotic at a stable dosage for at least 4 weeks before enrollment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bakırköy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology and Neurosurgery Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
| Istanbul University Cerrahpaşa - Cerrahpaşa Faculty of Medicine Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.